Re-appointment of M/s S Chhaparia & Associates as Cost Auditor for financial year ended 31 March 2026.
SURAKSHA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Suraksha Diagnostic reported strong FY2026 results with standalone revenue growing 21% to ₹30,068 lakhs and profit after tax at ₹3,406 lakhs (up ~1.9%). The Board also declared its first dividend of ₹0.50 per share (25% on ₹2 face value), subject to shareholder approval at the September 2026 AGM. Additionally, M/s S Chhaparia & Associates was reappointed as Cost Auditor for FY 2026-27, and M/s Suresh Surana & Associates LLP was appointed as Internal Auditor. Statutory auditors MSKA & Associates issued an unmodified opinion on both standalone and consolidated results.
The company delivered solid topline growth and declared its inaugural dividend, signalling improving cash generation. Cost auditor reappointment is routine and has no adverse implications for shareholders.